Ovarian cancer proteomic biomarkers for pembrolizumab response

Katherine Kleinberg(Vanderbilt University Medical Center), Courtney A. Penn(Vanderbilt University Medical Center), Dandi Huang(Billings Clinic), Julia Wulfkuhle(University of California, San Francisco), Susan R. Opalenik(Vanderbilt University), Rosa I. Gallagher(George Mason University), Brandie C. Taylor(Vanderbilt University Medical Center), B.J. Rimel(Cedars-Sinai Medical Center), Justin M. Balko(Vanderbilt University Medical Center), Xiaopeng Sun, Andres A. Ocampo(Vanderbilt University Medical Center), Emanuel F. Petricoin(Center for Biologics Evaluation and Research), Erica V. Carballo(Vanderbilt University Medical Center)
Gynecologic Oncology Reports
June 1, 2025
10.1016/j.gore.2025.101831
Cited by 0

Related Papers

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
|The Lancet Oncology|2014|586
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
|Nature Communications|2016|580
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
|The Lancet Oncology|2019|533